Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint

BACKGROUND: Alosetron is approved to treat women with severe IBS and diarrhea (IBS-D) who have failed standard therapy. In our study, we aimed to evaluate alosetron efficacy using new US Food and Drug Administration (FDA) endpoints and utilization in clinical practice. METHODS: This prospective, ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, Brian E., Nicandro, Jean Paul, Chuang, Emil, Earnest, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949923/
https://www.ncbi.nlm.nih.gov/pubmed/29774051
http://dx.doi.org/10.1177/1756284818771674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949923/
https://www.ncbi.nlm.nih.gov/pubmed/29774051
http://dx.doi.org/10.1177/1756284818771674

Ejemplares similares